Spectral AI Inc. reported fourth‑quarter and full‑year 2025 results that beat analyst expectations on both revenue and earnings. Q4 revenue reached $3.8 million, up 53.6% from $7.6 million in Q4 2024, while full‑year revenue totaled $19.7 million, a 33.1% decline from $29.6 million in 2024. The company posted a net income of $0.6 million for the quarter, driven by a $4.0 million gain in the fair value of warrant liabilities, and a net loss of $7.6 million for the year. Gross margin fell to 39.8% in Q4 from 44.0% in 2024, but the full‑year margin improved to 45.4% from 44.9% in 2024. Cash and cash equivalents stood at $15.4 million on December 31, 2025, up from $5.2 million a year earlier, giving the company a strong liquidity buffer as it moves toward commercialization.
The revenue beat of $0.87 million over the consensus estimate of $2.98 million was largely attributable to the company’s continued receipt of research and development revenue from its BARDA contract. While the mix of BARDA‑funded work shifted toward lower‑margin activities, the absolute dollar amount of R&D revenue remained robust, offsetting the decline in other revenue streams that are expected to taper as the company transitions to commercial sales. The quarter’s $3.8 million in R&D revenue was down from $7.6 million in the prior year, reflecting the winding down of BARDA reimbursements after the June 2025 FDA submission.
Margin compression in Q4 was driven by a lower percentage of reimbursed direct labor in the revenue mix, as the company moved closer to the completion of the base phase of the BARDA Project BioShield contract. This shift reduced the proportion of high‑margin direct labor revenue, pulling the overall gross margin down to 39.8% from 44.0% in the same quarter a year earlier. The full‑year margin improvement to 45.4% reflects a modest increase in the mix of higher‑margin revenue, partially offset by the decline in R&D revenue.
GAAP earnings per share for Q4 were $0.02, a $0.15 beat over the consensus estimate of –$0.13. The positive EPS was largely a result of the $4.0 million warrant liability gain, which offset operating losses. On a non‑GAAP basis, the company reported a loss of $0.11 per share, wider than the analyst estimate of a $0.129 loss, reflecting ongoing operating expenses as the company invests in product development and regulatory activities.
Management reiterated its 2026 revenue guidance of $18.5 million, unchanged from the prior guidance, and emphasized that the forecast does not include any commercial sales of the DeepView System. The guidance signals confidence in continued BARDA funding and progress toward FDA clearance, while also acknowledging that commercial revenue will not materialize until after regulatory approval. The company’s cash position and disciplined expense management provide the runway needed to support this transition.
"2025 was a pivotal year for Spectral AI, highlighted by the submission of our De Novo 510(k) application to the U.S. Food and Drug Administration (“FDA”) of our DeepView System for burn indication." "We continue to make significant progress along numerous fronts in preparation for the anticipated commercialization of this innovative diagnostic device. The reception of our technology at burn conferences in the U.S., UK, and Europe has been exceptional." "We ended the year in a strong financial position, especially with our cash balance above $15.0 million at year‑end, and we continue to manage expenses to ensure that spending aligns with our strategic priorities and commercialization. We are confident that we have the people, processes, and platform in place to prepare for the next exciting phase of our growth." "Fourth‑quarter 2025 research and development revenue of $3.8 million, down from $7.6 million in the prior‑year quarter, reflecting what management described as an anticipated reduction in reimbursed costs as the company neared completion of the base phase of the BARDA Project BioShield contract." "primarily to a lower percentage of reimbursed direct labor in the revenue mix." "changes in the warrant liability valuation, reduced borrowing‑related costs, net amortization of debt discount, and improved operating efficiencies as primary drivers of the year‑over‑year improvement.",
revised_sentiment_rating":4} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.